Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area

By  

Intervirology, Vol. 56, Iss. 3, 2013-01 ,pp. : 178-183

Karger

Access to resources Recommend Favorite

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 992-1001

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b hepatitis C virus infection according to an algorithm based on the drug Adherence, IL‐28B Gene Allele and Viral Response Trial (AG

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 11, 2015-11 ,pp. : 1091-1099

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of telaprevir‐based therapy for difficult‐to‐treat patients with genotype 2 chronic hepatitis C in Japan

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 7, 2015-07 ,pp. : 745-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of the peginterferon‐α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV‐co‐infected patients with the unfavourable non‐CC IL28B genotypes

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 21, Iss. 3, 2014-03 ,pp. : 178-188

John Wiley & Sons Inc

Access to resources Recommend Favorite